|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Celgene
|
|
gptkbp:activities
|
immunomodulatory
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:can_be_used_with
|
gptkb:dexamethasone
|
|
gptkbp:class
|
immunomodulatory drug
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
Phase 3
ongoing studies
|
|
gptkbp:contraindication
|
pregnancy
severe liver impairment
|
|
gptkbp:developed_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:discovered_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:beer
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pomalidomide
|
|
gptkbp:indication
|
gptkb:HIV-associated_Kaposi's_sarcoma
gptkb:relapsed_or_refractory_multiple_myeloma
|
|
gptkbp:ingredients
|
C13 H11 N3 O4 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
other immunosuppressants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L04 A X04
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 7 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Pomalyst
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
0 A0 D1 F1 B1 B
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
adults
|
|
gptkbp:related_to
|
gptkb:lenalidomide
gptkb:thalidomide
|
|
gptkbp:research
|
improves survival rates
effective in combination therapy
reduces tumor burden
|
|
gptkbp:research_areas
|
oncology
hematology
|
|
gptkbp:safety_features
|
risk of thrombosis
risk of secondary malignancies
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
thrombocytopenia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
191732-72-6
|